Anthem Biosciences Limited
Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs. The company was incorporated in 2006 and is based in Bengaluru, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockRule-based from financial data. Not advice.
Historically, Feb has averaged the highest return (+17.1%); Nov the lowest (-10.6%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.1%Negative MonthJan 2026: -8.06% | +17.1%Positive MonthFeb 2026: +17.07% | -6.3%Negative MonthMar 2026: -6.34% | +15.8%Positive MonthApr 2026: +15.76% | +2.2%Positive MonthMay 2026: +2.21% | -0.8%Neutral MonthJun 2026: -0.84% | +1.8%*Neutral MonthJul 2026: +1.81% | β | β | β | β | β |
| 2025 | β | β | β | β | β | β | β | +7.9%Positive MonthAug 2025: +7.89% | -7.0%Negative MonthSep 2025: -6.97% | -6.7%Negative MonthOct 2025: -6.71% | -10.6%Negative MonthNov 2025: -10.60% | +2.5%Positive MonthDec 2025: +2.51% |
| AvgΒ±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position β all Januaries together, all Februaries together, and so on β to show whether a given month has leaned positive or negative historically. βSimpleβ counts each month as +1 or β1. βWeightedβ gives larger moves more influence: +2 above +10%, β2 below β10%. With only 2 years of history for this asset, each monthβs score reflects a small number of observations β read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the assetβs full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each dayβs closing price by the price on January 1st of that year (or the assetβs first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in βAverage fromβ, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ1.84 K Cr | β | βΉ506.00 Cr | β | β | 20.5% | 29.8% | 34.9% |
| Mar 2024 | βΉ1.42 K Cr | β | βΉ375.00 Cr | β | β | 19.4% | 34.2% | -2.8% |
| Mar 2023 | βΉ1.06 K Cr | β | βΉ386.00 Cr | β | β | 22.2% | -14.1% | -4.9% |
| Mar 2022 | βΉ1.23 K Cr | β | βΉ406.00 Cr | β | β | 29.9% | 11.6% | 49.8% |
| Mar 2021 | βΉ1.10 K Cr | β | βΉ271.00 Cr | β | β | 38.7% | 74.2% | 191.4% |
| Mar 2020 | βΉ633.00 Cr | β | βΉ93.00 Cr | β | β | 22.1% | 1.1% | 20.8% |
| Mar 2019 | βΉ626.00 Cr | β | βΉ77.00 Cr | β | β | 23.3% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Revenue / Net Sales | 626 | 633 | 1,103 | 1,231 | 1,057 | 1,418 | 1,841 |
| Total Expenses | 454 | 451 | 695 | 666 | 626 | 912 | 1,151 |
| EBIT / Operating Profit | 172 | 182 | 408 | 566 | 431 | 505 | 690 |
| OPM % | 27% | 29% | 37% | 46% | 41% | 36% | 37% |
| Other Income | 21 | 21 | 37 | 49 | 139 | 70 | 109 |
| Finance Costs | 18 | 20 | 17 | 10 | 9 | 9 | 9 |
| Depreciation & Amortisation | 61 | 62 | 62 | 58 | 64 | 81 | 78 |
| Profit Before Tax | 114 | 121 | 366 | 547 | 498 | 485 | 711 |
| Tax % | 32% | 23% | 26% | 26% | 23% | 23% | 29% |
| Net Profit / PAT | 77 | 93 | 271 | 406 | 386 | 375 | 506 |
| EPS (βΉ) | 91.97 | 110.62 | 319.77 | 462.60 | 6.76 | 6.70 | 9.05 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Anthem Biosciences Limitedthis co. | βΉ35.38 K Cr | βΉ1.84 K Cr | 66.20 | 12.40 | 61.40 | 29.8% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |
